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ABSTRACT
Biodegradable alginate microcapsules (MC) are recently becoming widely used in
the biomedical field, and have shown effectiveness as a drug delivery system. Alginate
has been used in microencapsulation due to its simple gelling process, biodegradability,
excellent biocompatibility, and its stability under in-vivo conditions. Alginate polymer is
a natural polysaccharide derived from brown seaweed and has the ability to polymerize
rapidly in the presence of cations to form a porous matrix. In order to advance the
previous system for efficient protein and peptide delivery, we further lyophilized the
peptide-filled microcapsules and we were able to rehydrate, and test them for sustained
release. Electrospray method, as a microencapsulation technique, has been previously
used to encapsulate peptides and proteins successfully using alginate. A second coating
of poly-l-ornithine (PLO) polymer can be used to increase the integrity of alginate
microcapsules. Alpha-carboxy terminus 1 (αCT1) peptide, Human platelet lysate (HPL),
and bovine serum albumin (BSA) were examples of peptides and proteins that were
successfully encapsulated by our lab.
Cell-based therapies represent a revolutionary bio-technique that has been applied
widely in medicine. Recently, they have been successfully applied in treatment of
neurodegenerative diseases, eye diseases, cardiovascular disease, diabetes, liver disease
and cancer. Suppression of the host immune system is considered the main challenge in
such therapies. In order to avoid the side effects of immunosuppressive drugs,
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encapsulating cells into polymeric matrices is considered a promising strategy.
Encapsulation systems utilize permeable materials that allow diffusion of nutrients, waste
and therapeutic factors into and out of cells, while masking the cells from the host
immune response. In our model, we have been encapsulating ARPE-19, human immortal
cell line, that was genetically designed to express and secret CR2-fH protein to test them
for safe and effective long term inhibition in vivo. CR2-fH is a complement inhibitor
molecule that has been recently found to express promising therapeutic effects in both in
vivo and in vitro models of Age-related Macular degeneration (AMD). Furthermore,
human skeletal muscle differentiating cells (skMDC) that were recently used in
biomedical research to investigate skeletal muscle behavior, function, and ability to be
implemented in tissue regeneration field for further applications of disease advanced
therapies.
In this study we hypothesize that alginate encapsulation using high voltage
method can be enhanced and advanced further to use it in different clinical approaches
and applications. The present study shows the successful formation of alginate-poly-Lornithine microcapsules using the above-mentioned method, according to specific
parameters, to produce microcapsules about 200 m in diameter. The microcapsules
derived from this encapsulation technique according to our hypothesis can be freeze dried
without harming the shape of the microcapsules in which they retain the original shape
after hydration. The main purpose of lyophilization is to increase the shelf-life storage of
encapsulated biomaterials as well as preserve its activity to be used for treatment.
Moreover, the technique has the ability to preserve the metabolic activity of genetically
engineered ARPE-19 cells and skMDC cells resulting in effective and safe long-term
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drug delivery for treatment. In addition, hydrogel systems have been utilized in
combination with the previous approaches, lyophilized microcapsules and encapsulated
cells, for more improvements in regenerative medicine and targeted delivery therapy
fields.
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CHAPTER I
INTRODUCTION
1.1 Microencapsulation and Drug Delivery Systems
Drug delivery systems (DDS) are engineered approaches or technologies for
controlled release of therapeutic agents and/ or delivery of them to target organs in the
body in order to eliminate or minimize systemic side effects. Recently, DDS have been
improved steadily, and the interest in controlled release dosage forms has increased. DDS
that include carriers, composed mainly from lipids and/or polymers, and their associated
therapeutic agents on macro, micro, and nano scale are primarily designed to manipulate
biodistribution and pharmacokinetics of the associated drugs. In addition, DDS are
functioning as sustained release systems especially with advances in biotechnology
related to macromolecules such as proteins, peptides, oligonucleotides, and plasmids 1,2.
Microencapsulation systems are one of DDS that are recently getting more
attention in advancement for targeted delivery of therapeutic agents. Microcapsules
yielded from this technique are characterized by their semipermeable membrane that
allows diffusion of the encapsulated materials from the inner core. The permeability of
the microcapsules can be adjusted by coating with one or more layers which provide a
controlled release property or add protection of the encapsulated materials. There is a
diversity of materials that can be encapsulated successfully for different clinical
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applications such as peptides, proteins, enzymes, and antibiotics. Properties of
microcapsules (size and shape) are controlled by different parameters such as applied
voltage, spraying distance, flow rate, method of encapsulation, and polymer
concentration3. The synthesis procedures can vary such as electrospray method,
emulsification, jet flow, and solvent evaporation; which result in microcapsules with
different morphologies and shapes including spheres, cubes, rods, and irregular patterns3–
5

. There are two main categories in the field of electro-hydrodynamics: electro-spraying

and electro-spinning.
Microparticles, as drug delivery systems, have been developed due to the
advancement of pharmaceutical materials technology that allowed creation of polymeric
microcapsules using electrically charged fluids of different natural and synthetic
polymers. The polymeric microcapsules have distinctive properties in terms of shape,
particle size, drug loading, and profile release6. Currently, there are a wide range of
polymers that are used for microencapsulation technology including sodium alginate,
chitosan, poly-lactic-co-glycolic acid (PLGA), poly-ethylene glycol (PEG), poly-lornithine (PLO), and poly-l-lysine (PLL)7–12. Unique properties of each polymer such as
biocompatibility, viscosity, reactivity with the encapsulated materials, and charge; make
it unique for its desired application.
All the different encapsulation procedures share the same methodology concept.
One of the polymers used for encapsulation is placed in a positively charged syringe
attached to a high voltage generator, and the flow rate of the polymer is controlled by
using a syringe driver or pump where the polymer is extruded to a grounded gelling bath.
A cone jet is formed at the needle tip due to application of an electric polarization stress
2

(electrically conductive solution passes through electrical potential difference), flow and
gravity. The cone jet is a formation of conical shape of liquid at the needle tip where the
charged particles of the liquid accumulate at the apex of the cone. Once a minimal steady
state has been reached of both flow and electrostatic voltage, the charged particles
separate from the apex and break into reproducible droplets. The material’s nature and
properties plays main role in this stage of the procedure13,14. Without applying electrical
forces to the procedure, the droplet will be controlled by the surface tension of the liquid
polymer and effect of the gravity15. The formed droplet, as micro or nanoparticles, will
finally be collected in a grounded solution (as in electrospray method) or device (as in
electrospinning method). Both methods are becoming more popular as methods of drug
delivery because they can be easily adjusted or altered to form particles possessing a
desired release rate and pharmacokinetics. On the other hand, other methods of
encapsulation may require additional steps such as heat, shear stress, and pressure which
might negatively affects the encapsulated therapeutic agents by decreasing its
functionality or degrading its structure3. Our method of interest in this work is the
electrospray method to produce spherical microcapsules using sodium alginate as a
primary polymer.
Alginate is a natural polymers and it is used widely in microcapsule formation
because of its unique properties including low toxicity, biocompatibility, mechanical
stability, bioadhesive properties, gelling properties and abundance2,16,17. It is a naturally
occurring polysaccharide extracted from brown seaweed, and it’s chemical structure is
composed from a linear copolymer of (1–4)-linked β-D-mannuronic acid and α-Lguluronic acid as it is described in Figure 1.1

3

10,18–23

. Different applications of alginate

has been explored such as its usage as coating material, preparation of controlled release
drug delivery systems including microspheres, gels, and membranes; as well as forming a
hydrogel when crosslinked to cations such as calcium of barium16,24,25.
1.2 Freeze drying—Lyophilization
Lyophilization, or freeze drying, is a technique often used mainly to enhance the
stability and shelf life of pharmaceutical products. This technique is based on dehydrating
a pre-frozen material at low temperature and low pressure, and resulting in formation of a
porous structure. In addition to preserve color, scent, and shape of lyophilized materials,
freeze drying technique keeps the biochemical characteristics and pharmacological
properties to the greatest extent. Freezing and drying stresses applied by lyophilization
could tend to destabilize or denature protein compounds, but different proteins endure
freezing and drying stresses to various degrees. Although lyophilization of protein
formulations is a challenging process, it is considered a common procedure in the
pharmaceutical field to improve stability of therapeutic proteins especially to maintain
their original characteristics upon reconstitution26–29. Freeze drying has been used
previously to dehydrate proteins, plasma, vaccines, blood platelets, and sperm cells and it
has been shown to increase their shelf-lives29–34. Also, seeking activity preservation of
most biological materials containing live bacteria and viruses through freeze drying
become widely used to ensure long term preservation.
The lyophilization process is typically performed initially by freezing the
biological material to freezing temperature range of (-50C)-(-80C), followed by drying
the biological material under vacuum to remove frozen water from the material at two
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different stages of drying. Primary drying at temperatures below 0C and the drying rate
at this stage is limited to avoid foaming of the product due to the high temperature and
the excess liquid (solvent) amount at this stage. Then the secondary drying stage begins
at temperatures above 0C to bring the residual moisture of the biological material to an
optimum level. If the moisture content is above or below the optimum value, the effective
life of biological material will be reduced35–37.
Freeze drying of microencapsulated human retinal pigment epithelial cells
(ARPE-19) has been shown to be successful in a recent study38. It has been demonstrated
that the cells were able to retain their viability and structural integrity after freeze
drying39. Cell were encapsulated in polycation coated alginate microcapsules and
lyoprotective solutions such as trehalose that protects proteins, cellular membrane, and
nucleic acids from the harmful effects of the dehydration32,40–43. Trehalose replaces the
cellular water molecules and forms intracellular glass to protect the viability of the cells
from the damage that can be caused by the dehydration. Also sugars and antioxidants can
be added in different protocols for the same protection purposes43–47.
1.3 Cell encapsulation
Cell encapsulation technology refers to entrapment of living cells as targeted
delivery systems. Encapsulated cells can be used for two purposes: delivering living,
functional cells to the target organs for tissue engineering purposes; delivering
therapeutic molecules produced from genetically engineered cells to a targeted tissue or
organ. More important, this technique provides the advantage of long term targeted
treatment without the necessity for recurrence. As described in Figure 1.2, cells after
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encapsulation will be entrapped within a polymeric semipermeable membrane that allow
influx of nutrients and oxygen; and outflux of metabolic waste products and therapeutic
molecules. The membrane also protects the cells from the host immune system48.
Cell encapsulation technique is a promising approach in the development of cell
based therapies to treat acute and chronic illnesses. Recently, research studies are focused
on encapsulating different cell types such as ARPE-19 cells, peripheral blood
mononuclear cells, non-human primate multipotent stromal cells, mesenchymal stem
cells, and islet cells39,49–52. Alginate polymer is widely used in encapsulating different
types of cells and the purification degree of alginate is playing a great role in the success
of cell encapsulation process. It has been shown that poorly purified alginate resulted in
failure of many microencapsulation processes; indeed, ultra-purified raw product (clinical
grade) of alginate in combination with PLO showed to be highly proficient in rendering
immunity stimulation of the host body where the mannuronate dimeric blocks of alginate
covalently bound to PLO49.
In a previous clinical study it has been shown that cells encapsulated within
alginate/PLO fabricated microcapsules had enough durability and robustness over a long
period of time lasts up to 5 years without any immunity sensitization49. The team of this
study was able to retrieve physically intact microcapsules after 5 years post-transplant
from one of the patients with type I diabetes included in the study. Although the study
was successful in transplanting encapsulated islet cells in diabetic patients for a long
period of time without any adverse effects, no therapeutic effect has been recorded
including regeneration of native islet cells or downregulation of plasma glucose levels.

6

However, such a successful clinical study brings motivation and hope that this technique
can be developed to play a vital role in cell targeted therapy in the near future49.
1.4 Hydrogel
Hydrogels are composed of hydrophilic polymer chains that form a threedimensional system with high water content. The characteristics and properties of each
hydrogel depend on the type of polymer used to prepare it, and also can define the
purpose of use or the results to be pursued of each application. These properties are
varied such as: biocompatibility, elasticity, capability to mimic extracellular matrix
(ECM), and adaptable chemical properties53–55. Polymers used in preparing hydrogels are
classified in two categories: naturally derived from materials such as collagen, alginate,
chitosan, and hyaluronic acid or synthetically derived from materials such as poly
hydroxyethyl methacrylate (poly HEMA) and poly ethylene glycol (PEG)56,57. Hydrogels
are gaining attention in biomedical research field and regenerative medicine due to their
ability to serve as cell and drug delivery therapies, and due to the advancement
accomplished in biomaterial systems which set the foundation for therapeutic strategies
54,58–62

.
Stem cell therapy using hydrogel as a bioactive material is one of the important

applications of hydrogel where it is known as regulation of stem cell fate in the field of
cell delivery therapy. Hydrogels act as platform that allows better viability, proliferation,
and retention of the stem cells63–67. The similarity in the structure between hydrogel
scaffolds and extracellular matrix of many tissues is beneficial and increases the
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successfulness rate of this approach in engineering tissue replacements; as well as in drug
and growth factor delivery68.
Usage of natural polymers in preparing hydrogel scaffolds is becoming more
popular in regenerative medicine recently. Collagen is considered one of the most
commonly used natural polymers in this field due to its biocompatibility,
biodegradability, and high versatility69–71. It is one of the main components of
extracellular matrix proteins existing in the mammalian tissue, and it is derived from skin
and tissue of vertebrate species67,72,73. It has been shown previously that type I collagen
based hydrogels can cooperate with polyacrylamide to create matrix models of scars
which considered soft matrices that exhibit less cell to cell noise. Moreover, type I
collagen is able to covalently cross-link to protein patterns to stimulate interactions
between the hydrogel surface and the cells74,75. Collagen hydrogels have been used with
great success as three-dimensional media for cell culture and showed promising results
acting as scaffolds for engineered tissues and tumors. More important, adjustment of
quantitative characteristics of collagen hydrogel properties is a critical phase to fulfill
engineering requirements and match specific tissues in order to be considered as viable
tissue mimics76.
My studies aim to further investigate different approaches to test the hypothesis
that microencapsulation technique is a unique tool or device which could be advanced to
fulfill the necessity of different clinical applications and therapies. These studies are
described in the following chapters:
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Chapter II: The role of lyophilization process in advancing microencapsulation
technique.



Chapter III: The effect of electrospray method of encapsulation on the viability of
living cells within alginate based microcapsules.



Chapter IV: Involvement of hydrogel systems in advancing alginate based
microcapsules.
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Figure 1.1 The chemical structure of sodium alginate polysaccharide building units.
(G) Glucuronic acid, and (M) Mannuronic acid. Image produced by the Food and
Agriculture Administration of the United Nations.
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Figure 1.2 Schematic illustration of cell encapsulation technology.
(Reproduced with permission from Bhujbal SV, de Vos P, Niclou SP. Drug and cell
encapsulation: Alternative delivery options for the treatment of malignant brain tumors.
Advanced Drug Delivery Reviews. 2014;67-68:142-153. doi:10.1016/j.addr.2014.01.010)
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CHAPTER II
THE ROLE OF LYOPHILIZATION PROCESS IN ADVANCING
MICROENCAPSULATION TECHNIQUE1
2.1 Background
Targeted drug delivery and controlled release delivery are considered key areas in
drug delivery systems. Advancements in technology are becoming more focused on
precisely targeting therapeutic agents to the exact cell, tissue, or organ; and in controlling
the fate of a therapeutic agent entering the body77. The encapsulation method is a major
factor in encapsulation and release of therapeutic agents. Other factors also control the
characteristics of microcapsules; the type of polymer icluding its molecular weight,
viscosity, and surface charges contribute in defining its characteristics as well as the
characteristics of formed microcapsules78. Using electrospray method as a method of
fabrication of polymers is the method of choice in this study. Also, alginate is the core
polymer used to form microcapsules in adjacent to poly-l-ornithine which is used as a
double coat to increase the integrity and enhance the selective porosity of the
microcapsules79,80. In this work, we hypothesized that lyophilization of A-PLO
microcapsules might advance this technology and enhance its usage for a variety of
applications.
1

Parts of this chapter have been excerpted from the following research article:
Belhaj M, Menon V, Rohrer B, Potts J. Alginate Microcapsule Technology and Impacts
on Cell Therapy Development. Microsc Microanal. 2017;23(S1):1214-1215.
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Lyophilization is a process that operates at different conditions and temperatures
which may result in products with different characteristics26,81,82. However, lyophilization
has been used widely to preserve different biological materials used for a variety of
clinical purposes such as antibiotics, vaccines, proteins, and cells31,35,36,45,83. Moreover,
lyophilization is a promising procedure in maintaining different therapeutics, including
pharmaceuticals and biological materials, in a dry form for long-term storage, transport,
and rehydration at the time of clinical administration84.
2.2 Materials and Methods
Microencapsulation:
Electrospray Method was used to prepare the microcapsules7,85,86. Sodium
alginate (Sigma-Aldrich, St. Louis, MO, USA) was mixed under sterile conditions at a
concentration of 2% w/v. The resulting mixture was purified by filtration at 0.2 mm.
Human platelet lysate (HPL) (Cook Biotech) was added to the alginate and small aliquots
(280 mL) of filtered alginate and HPL mixture were loaded into a 3cc syringe and
attached to a syringe pump. Alginate-poly-Ornithine (A-PLO) microcapsules were
produced by a one-step method. Polymer solution of poly-l-ornithine (Alfa Aesar Lornithine hydrochloride 99%) was mixed at a 0.5% w/v in 0.15 M calcium chloride
(CaCl2) (Sigma-Aldrich). The pH was buffered accordingly by 0.1 M HEPES.
A volume of 30 mL of the gelling solution was placed in a beaker below the
syringe pump as a gelling bath, with a needle-to-bath working distance of 7 mm (spray
distance). A high voltage generator was attached to the tip of 30cc blunt tip needle
(purchased by Amazon Supply, Seattle, WA, USA) with a ground placed in the CaCl2
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solution. Next, a constant voltage was set on the high voltage generator to pass a field of
current through the needle tip attached to the syringe. The syringe pump was started to
push the filtered alginate solution through the needle tip and into the CaCl2 gelling bath
with a flow rate of (60 mm/h). As the extruded alginate was pushed by the syringe pump,
it passed through the positively charged needle into the negatively charged CaCl 2 gelling
bath creating spherical microcapsules. The voltage remained constant throughout the
microcapsulation process by setting the generator prior to starting the syringe pump.
Synthesized microcapsules were allowed to gel 12 minutes then removed from the gelling
bath post-synthesis and rinsed several times in sterile deionized water to remove any
traces of CaCl2.
Lyophilization of Microcapsules:
Microcapsules were prepared as mentioned above. The suspended microcapsules
in deionized water were frozen using liquid nitrogen. Once the sample was frozen, the
beaker was covered with parafilm or a piece of foil and pierced many times to allow
escaping of water vapor. Then the sample was placed into a lyophilizer vessel (Labconco,
Kansas City, MO, USA) overnight to get a dry powder of microcapsules. The lyophilized
microcapsules were rehydrated using deionized water and tested morphologically to
ensure complete recovery and shape retaining.
Scanning Electron Microscopy (SEM) of Microcapsules:
It was performed to characterize surface morphology of lyophilized and nonlyophilized microcapsules and examine the effect of lyophilization process on
microcapsules morphology. Prior to SEM preparation, microcapsules from both groups
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were exposed to UV power at 9,000 x 100 on a plastic petri dish for 30 minutes. An
incubation of 24 hours at 4C was then allowed. Exposure to UV power has been done to
increase microcapsule rigidity that insures maintaining the shape during harsh SEM
processing. The method of processing was carried out based on a modified protocol using
the osmium-tannic acid osmium method (Murphy, 1980). A buffer of 0.1M Na
cacodylate, 3mM CaCl2 at pH 7.2 was used initially to wash microcapsules followed by a
buffered fix of 2% paraformaldehyde, 2% glutaraldehyde, and 0.1% ruthenium red.
The microcapsules were then rinsed with (Na cacodylate/ CaCl2) buffer and
placed in a secondary buffered fix consisting of 1% osmium tetroxide and 0.1%
ruthenium red. The same buffer solution, (Na cacodylate/ CaCl2) buffer, was used to
rinse fixed microcapsules, and then placed in a series of alternating buffered fixatives
containing either 1% tannic acid in 1% glutaraldehyde or 1% osmium tetroxide. Rinses in
these buffered fixatives were repeated eight times at 20 min each with rinsing with buffer
in between steps. Finally, the microcapsules were rinsed with water to remove any buffer
residues, followed by deydrating in a series of ethanol baths, critical point drying
(Tousimis Samdri PVT 3B; Tousimis, Rockville, MD, USA), and gold sputter coating
(Cressington 108 Auto/SE; Cressington Scientific Instruments Ltd., Watford, UK). SEM
images were taken using a JEOL JSM-6300 SEM at 10 kV (JEOL Ltd., Tokyo, Japan).
Microencapsulation and Release Profile of BSA Protein:
Release profiles of BSA were studied over 10 days from alginate microcapsules
formation or from lyophilized microcapsules rehydration at different temperature
settings, 37C and room temperature. In our studies we have elected to study release in
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alginate microcapsules before lyophilization and rehydrated microcapsules after
lyophilization.
For these experiments, encapsulation parameters were kept constant at 6.0kV
initial voltage, flow rate of 60mm/hr, and 7 mm spray distance. Initial BSA protein
concentration was kept constant at 1mg/ml. Alginate concentration was also kept constant
at 2%, while the CaCl2 gelling bath was synthesized at 0.15M CaCl2 as previously listed.
As it has been suggested in a previous study held in the lab, pH as well kept constant at
7.3. Microcapsules used for release profiles were not coated with poly-l-ornithine
polymer. Post synthesis, microcapsules were rinsed in deionized water to remove excess
gelling solution. The microcapsules were then re-covered in 0.5mL deionized water, with
time points taken over 10 days. Early time points of 1, 2, 4, 6, and 8hrs were taken to
account for early burst release of peptide from the microcapsules. Analysis of peptide
concentration was performed using a Micro BCA protein assay kit (Thermo Scientific)
with BSA standard solution for our standard curve. All tests were run on a BioTek
Synergy 2 spectrophotometer.
2.3 Results
Microencapsulation technique in our lab has been performed using electrospray
method under specific parameters to produce 200 m microcapsules in diameter. The
voltage was 6.0 kV, the flow rate was 60 ml/hour, the spray distance was 7 mm, and 2%
concentration of alginate solution. Also, the microcapsules were coated with poly-lornithine to increase the integrity of alginate microcapsules. Before processing the
microcapsules for electron scanning microscopy, the microcapsules were crosslinked
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using ultraviolet cross linker to increase their stiffness in order for the microcapsules to
maintain their shape during the preparation protocol for microscopy. As shown in Figure
2.1 A, the microcapsules were spherical in shape at its hydrated state with an average
diameter of 200 m. Microcapsules after encapsulation process were washed thoroughly
to remove any traces of CaCl2; then the microcapsules were loaded into lyophilizer for
dehydration. Dried microcapsules appeared as white powder, and its structure appeared to
be shrunk when examined with light microscopy and SEM as it is shown in Figure 2.1 B.
Adding deionized water to the lyophilized microcapsules led to its rehydration
and regaining almost the original spherical shape compared to control microcapsules
(before lyophilization). In Figure 2.1 C, rehydrated microcapsules appeared to have rough
surface compared to control microcapsules; however, most of the microcapsules retained
back their spherical appearance where very few rehydrated microcapsules get burst after
rehydration.
Loading efficiency experiments were conducted on four samples. Two identically
synthesized sets of microcapsules, one used immediately after encapsulation process and
one after rehydration following lyophilization, were both analyzed for release at 37C
and room temperature. Our preliminary data in Figure 2.2, indicated a rapid initial burst
of BSA prior to the initial 1 hour time point in the examined samples. Release from nonlyophilized microcapsules at room temperature does not show the initial burst release,
and it shows a delayed release until day 6 of incubation when it starts releasing. Previous
reports have suggested that the insets of release are at the five hours of release for better
appreciation of the rapid release of peptide85. The fluctuating release of BSA over all the
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samples is not clear. The impact of lyophilization and incubation temperature on BSA
release is unknown and must be further investigated in order to determine significance.
2.4 Discussion
A-PLO microcapsules previously showed a great potential as a controlled release
delivery system of connexin 43 peptide to increase wound healing rates in vivo80,85.
Parameters of encapsulation procedure are what control the characteristics of the
microcapsules produced. Nature and features of polymers have played an integral role in
advancements of delivery systems which defines the characteristics of microcapsules.
Accordingly, in this study we are using electrospray method to produce
approximately 200 m microcapsules by adjusting alginate concentration, flow rate,
spraying distance, and voltage rate. Our main goal is to optimize this technology and
improve its versatility for variety of clinical applications; therefore, lyophilization is one
of the approaches that will be examined in the current study. Lyophilization, freeze
drying, has been utilized since 1958 to enhance the pharmaceutical products in order to
be utilized at different administration strategies87.
As demonstrated through our results in Figure 2.1 that A-PLO microcapsules
were successfully lyophilized; not only that but also they were able to retain their
morphology back after rehydration. The microcapsules shown were empty, not loaded
with any material. Proteins were one of the biological materials to be lyophilized
successfully for stability and storage purposes. Although lyophilization was ideal to
prepare solid protein pharmaceuticals achieving stability at acceptable storage shelf life;
however, this process generates different stresses such as temperature changes, vacuum
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forces, pH changes, and formation of ice crystals. Protein denaturation at various degrees
might occur as a result of exposure to all of the stresses listed earlier26,87. Numerous
research studies have been conducted to identify critical effects of protein lyophilization
on protein stability and effectivity37,82,88. It has been shown that the need for stabilizers is
very critical in maintaining encapsulated biological materials’ effectivity during freeze
drying and storage afterwards as well as preserve the microcapsules structure40,42,89. The
results shown in our study indicates that the lyophilization process was capable of
preserving the original structure of our alginate-PLO microcapsules. However, further
investigations needed to verify the effects lyophilization on characterizations of
microcapsules which serve as controlled release delivery system.
Release profiles of biomaterials have proven to be controlled by different factors
including encapsulation parameters and incubation environment. As a result, it has been
previously shown that release of CT1, a low molecular weight peptide, can be
controlled by altering extrusion parameters or by including an additional polymer coating
to in order to interfere with diffusion pathway85. According to our preliminary data, the
effect of lyophilization on release of BSA is not clearly understood. In addition, the
change in incubation temperature presumed to have an effect that was not clearly
correlated to the control of BSA release from alginate microcapsules. Further
investigations are highly recommended to identify a clear vision on the effect of
lyophilization on releasing of encapsulated biomaterials which will dramatically affect
the feasibility of lyophilization as technique intended for long term storage of
encapsulated therapeutics.
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Figure 2.1 Light microscope and SEM images of empty alginate microcapsules.
(A) Microcapsules before lyophilization in a hydrated form and spherical shape with a
diameter of 200 m. (B) Lyophilized microcapsules that appear shrunk in a dehydrated
form. (C) Lyophilized microcapsules were rehydrated by adding DI water where the
microcapsules retain their spherical shape. Scale bars are 100 m (LM) and 10 m
(SEM).
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Figure 2.2 Release profiles comparison of loaded BSA within non-lyophilized and
lyophilized alginate microcapsules at different incubation temperatures.
All 2% alginate microcapsules were loaded with BSA at concentration of 1 mg/ml. The
microcapsules were synthesized and gelled in a 0.15M CaCl2 bath at a pH of 7, a flow
rate of 60 mm/hr, and a voltage of 6.0 kV. (A) Comparing release profiles of BSA in
water at 37C between non-lyophilized and lyophilized microcapsules. (B) Comparing
release profiles of BSA in water at room temperature between non-lyophilized and
lyophilized microcapsules. Measurements were examined using Micro BCA protein
assay at 562nm.
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CHAPTER III
THE EFFECT OF ELECTROSPRAY METHOD OF ENCAPSULATION
ON THE VIABILITY OF LIVING CELLS WITHIN ALGINATE BASED
MICROCAPSULES2
3.1 Background
Currently available drug delivery systems cannot fulfill the demand of several
diseases for tight regulation of therapeutic factors. Accordingly, cell therapy shows a
potential to serve as a new approach of delivery systems for multiple diseases including
neurodegenerative diseases, diabetes, and muscle diseases48,90. Genetically engineered
cells, stem cells, and primary cells are the main focus of recent research studies with the
aim of avoiding the implant rejection by host immune response and maintaining cell
viability. Therefore, cell encapsulation emerges as a promising therapeutic strategy for
targeted management of numerous health problems. The goal of cell encapsulation is to
serve as a drug delivery tool, sustained release of therapeutics from encapsulated cells,
and regenerative medicine tool, delivering cells to particular tissues49,90.Utilizing
encapsulated cells as a therapeutic application was pioneered by Lim and Sun early in
1980 when they demonstrated the ability of inducing normal glycemic levels in diabetic
rats by implanting microencapsulated islets91.

2

Parts of this chapter have been excerpted from the following research article:
Belhaj M, Menon V, Rohrer B, Potts J. Alginate Microcapsule Technology and Impacts
on Cell Therapy Development. Microsc Microanal. 2017;23(S1):1214-1215.
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Our aim in this work is utilizing A-PLO microcapsules as a carrier for different
cell types genetically modified ARPE-19 cells, expressing inhibitory factor CR2 and
CR2-fH, and skMDC cells that might be beneficial for future clinical approaches as
delivery systems.
3.2 Materials and Methods
Cells Culture:
Human retinal pigment epithelial cells (ARPE-19), cell line, were cultured in
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS). The medium was replaced every 2-3 days, and the cells were passaged after
70%-80% confluence was reached. Cells were used between 24-27 passages.
ARPE-19 cells were transfected using AAV- mediated delivery with plasmid
constructs of CR2 and CR2-fH to express CR2 and CR2-fH proteins. These transfected
cells were provided by our collaborators, Dr. Baerbel Rohrer’s lab, at The Medical
University of South Carolina, Department of Ophthalmology. The cells were cultured in
High glucose/without L-glutamine- Dulbecco's Modified Eagle Medium (Sigma
Aldrich) supplemented with10%

dialyzed FBS (Sigma Aldrich), 2% Glutamine

synthetase expression medium (GSEM- Sigma Aldrich), and 0.28l/ml L-methionine
sulfoximine (MSX- Sigma Aldrich). The medium was replaced every 2-3 days, and the
cells were passaged after 70%-80% confluence was reached. Cells were used between
third and fifth passage.
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Primary human skeletal muscle derived cells (skMDC) were obtained from Cook
Myosite( Pittsburgh, PA). skMDC were cultured in MyoTonicTM basal medium
supplemented with MyoTonicTM growth supplement. Cells were cultured according to the
supplier recommendations at 37 °C and 5% CO2 and maintained below 80% confluence.
For differentiating the cells, the growth media will be replaced with MyoTonicTM
differentiation media (DMD- Cook Myosite) after cells reach confluence, and exchanged
after 2 days. The differentiation will be apparent within 3-4 days following replacing the
media.
Cell Encapsulation:
Electrospray method of microencapsulation has been used to encapsulate the
targeted cells. In this method, sodium alginate (Sigma-Aldrich) was mixed with DI water
under sterile conditions at concentration of 2% w/v and purified by filtration at 0.2 mm.
Alginate solution (300 l aliquots) were loaded into a 3cc syringe and attached to a
syringe pump, and pumped through a needle (30G blunt tip; Small Parts, Inc.,
Logansport, IN, USA) to a gelling bath placed in a beaker below the syringe at 7 mm of a
needle to bath spraying distance. The gelling bath contains a volume of 40 mL of 10 mM
HEPES buffered saline containing 100 mM calcium chloride (CaCl2) (Sigma-Aldrich),
and 0.5% w/v poly-L-ornithine (PLO) (Alfa Aesar) that forms a second coating to the
microcapsules as one step method for adjusting the porosity. The needle tip connected to
a high voltage generator while the gelling bath grounded. By applying high voltage
between positive and grounded bath, alginate is extruded from the needle tip to the
gelling bath where calcium ions (Ca2+) replace sodium ions (Na+) forming alginate
microcapsules coated with PLO and cells mixed with alginate solution will be trapped
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inside the microcapsules. Cells were trypsinized, centrifuged, and washed with 10 mM
HEPES buffered saline solution (pH 7.4), and a final cell concentration of 1x106 in
alginate solution were adjusted. Constant parameters of 60mm/hr flow rate and 6.0kV
initial voltage were adjusted to produce microcapsules size of 200 m. The size of the
microcapsules can be monitored by adjusting flow rate and voltage applied in which
150 m diameter microcapsules can be retrieved by applying parameters of 30mm/hr
and initial voltage 8kV. Formed microcapsules containing cells were washed with
washing solution (10 mM HEPES buffered saline containing 1.5 mM CaCl2, pH 7.4)
twice, and then incubated with suitable media in a humidified incubator at 37C and 5%
CO2.
Cell recovery:
The cells were released from alginate microcapsules by adding 55 mM Sodium
citrate in 10 mM HEPES buffered saline (pH 7.4) to the encapsulated cells with gentle
shaking for 5 mins at room temperature. In this step, calcium ions will replace sodium
ions in the microcapsule structure resulting in diluted sodium alginate and releasing the
cells from the microcapsules. Furthermore, the cells were centrifuged at 1200 rpm for 5
mins and incubated with media at 37C and 5% CO2 for 24 hrs.
Cell viability (Live/Dead) assay:
Encapsulated cells—after incubating the encapsulated cells for 24 hrs,
approximately 30 microcapsules were washed twice with washing solution (10 mM
HEPES buffered saline containing 1.5 mM CaCl2) and stained for live-dead viability.
Live/Dead assay kit (Molecular Probes) was used to evaluate the viability of cells after
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encapsulation. According to the manufacturer’s instructions, CalceinAM indicated viable
cells by green fluorescence (excitation/emission 495/515 nm), whereas Ethidium
homodimer-1 indicated dead cells by red fluorescence (excitation/emission 495/635
nm). Encapsulated cells in washing solution were mixed with Calcein AM and Ethidium
homodimer-1 at final concentrations of 2 M and 4 M respectively, and incubated for
30-45 mins in dark at room temperature. After staining, microcapsules were washed
twice with washing solution and imaged using Invitrogen EVOS FL Auto Cell Imaging
System (Thermo Fisher Scientific, Waltham, MA).
Encapsulated ARPE-19 cells in hydrogel— hydrogel was washed with PBS to
remove any media traces and stained for encapsulated cells viability. Live/Dead assay kit
(Molecular Probes) was used to evaluate the viability of cells after encapsulation and
mixing with collagen hydrogel. According to the manufacturer’s instructions, CalceinAM
indicated viable cells by green fluorescence (excitation/emission 495/515 nm), whereas
Ethidium homodimer-1 indicated dead cells by red fluorescence (excitation/emission
495/635 nm). A cocktail of Calcein AM and Ethidium homodimer-1 at final
concentrations of 2 M and 4 M respectively was added to the hydrogel and incubated
for 30-45 mins in dark at room temperature. After staining, excess amount of staining
solution was washed with PBS and we imaged the encapsulated cells in the hydrogel
using Invitrogen EVOS FL Auto Cell Imaging System.
Immunofluorescence analysis of the skMDC:
skMDCs were trypsinized from confluent plates and then grown overnight on 24
well plate with initial seeding density of 10,000 cells per well. Cells then were fixed with
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2% formaldehyde for 5 minutes and permeabilized with PBS- 0.1%Triton X-100 for 10
minutes. Fixed cells were washed with PBS and incubated at room temperature with
Glycine then with 5% BSA/PBS for 30 minutes each in order to stop the fixation reaction
using formaldehyde, and block non-specific protein binding accordingly. Cells after
blocking were washed and incubated overnight at 4C with Desmine, MyoD, and Pax-7
(Santa Cruz Technologies, Inc), 1:50 each. After washes, cells were incubated with 1:100
Texas Red (TX)-conjugated goat anti-mouse antibody (Jackson ImmunoResearch
Laboratories, West Grove, PA) together with DAPI for nuclear staining (Invitrogen/ Life
Technologies). Samples were analyzed on Invitrogen EVOS FL Auto Cell Imaging
System (Thermo Fisher Scientific, Waltham, MA) in the Instrumentation Resource
Facility (IRF) at the USC School of Medicine. Cells were observed with a 10X objective
lens, using a DAPI filter to visualize nuclei and a TX filter for Desmin, MyoD, and Pax7.
Results were observed in three separate experiments.
3.3 Results
Encapsulation of ARPE-19 cells:
Electrospray method at voltage rate of 6.0 kV enabled us to encapsulate ARPE-19
cells within 200 m A-PLO microcapsules as it is shown in Figure 3.1(B). Encapsulated
cells were then incubated in 10% FBS DMEM media at 37C/ 5% CO2 for a period of
time, microcapsules were imaged at different time points 3days, 6 days, and 20 days. As
it is shown in Figure 3.1 the encapsulated cells were proliferating inside the
microcapsules and appeared as clumps of cells. After 20 days of incubation, the
microcapsules start to burst and cells find their way outside the microcapsules as shown
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in Figure 3.1 (E). We revealed that FBS supplement in media has to be decreased from
10% to 2% to slow down their proliferation to prevent losing the microcapsules.
ARPE-19 cells viability test after encapsulation and their recovery from microcapsule
structure:
After encapsulation and incubation in 10% FBS media for 3 days, cells were
stained for live/ dead assay to evaluate their viability. Green color indicates viable cells
whereas dead cells were stained red. In Figure 3.2 (A), Cells in green (viable) were more
than dead cells (Red).
We examined the ability of the cells to be recovered back from microcapsules and
their ability to be incubated and proliferate after exposure to high voltage rate during
encapsulation. Encapsulated cells were incubated in 55 mM sodium citrate solution
HEPES buffered saline. Sodium ions from the solution will replace calcium ions attached
to alginate which will convert it into a soluble form and allow us to collect cells after
centrifugation. Recovered cells were cultured back in media and incubated at 37C and
5% CO2. Cell showed viability after being cultured back in their desired media, and we
were able to passage it up to 3 times after recovery.
Encapsulation of genetically modified ARPE-19 cells, viability, and recovery:
Genetically modified ARPE-19 cells were provided by our collaborators from
MUSC which expresses CR2 and CR2-fH proteins. Cells were encapsulated successfully
as indicated in Figure 3.3 B and examined for viability where the viable cells were highly
found in our sample; dead cells were barely found in our sample of live/dead assay as
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shown in Figure 3.3 (A). Cells were then recovered from microcapsules and incubated in
media as shown in Figure 3.3 (C) where the cells showed viability after recovery and they
were passaged for up to 3 times.
Encapsulation of skMDC cells, viability, recovery, and differentiation:
In Figure 3.4, skMDC cells encapsulated using the same method of encapsulation,
and the encapsulated cells examined for viability where in Figure 3.4 (C) most of the
cells were green indicating its viability.
Cells were recovered and were recovered back in media as shown in Figure 3.4
(D). In addition, a group of recovered cells were cultured in differentiating media Figure
3.4 (E) where the cells showed viability in the new media and incubated to give them a
chance to differentiate into skeletal muscles.
Staining skMDC cells for myogenesis markers Desmin, MyoD, and Pax-7:
The main purpose of staining the cells for myogenesis markers is to examine the
effect of encapsulation process has on the cell viability and metabolic activity. Staining
skMDC cells against the myogenic markers showed that the cells from the entire 3 group:
Control (before encapsulation), recovered, cells in differentiation media (differentiated),
were able to express MyoD, desmin, and Pax7. Nuclei were stained blue (Dapi) while the
targeted protein stained in red as it shown in Figure 3.5.
Freezing the encapsulated cells was another aspect that we utilized with ARPE-19
cells. After encapsulation and incubation in media for 3 days, we changed culture media
to a freezing media were the encapsulated cells mixed with and prepared for freezing.
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Vials of encapsulated cells were stored in Mr. Frosty and kept at -80C for up to one
week. Finally, the encapsulated cells were thawed and cultured back in supplemented
media, and then they were tested for viability using live/dead assay. As shown in Figure
3.8, the cells were stained in green indicating that their viability still preserved; red signal
indicating dead cells was barely expressed.
3.4 Discussion
Since enhancement of A-PLO microcapsules is the main goal of this work, cell
encapsulation is another approach in which we utilize our microcapsules to encapsulate
different type of cells. The polymer membrane serves as immunoisolation barrier for the
cells intended for applications as therapeutic delivery system and regenerative medicine.
Indeed, there are some preliminary clinical studies of prolonged survival of cells;
however, cell encapsulation technology has not yet accomplished the expected clinical
advances49,92. Recently, a wide range of research studies focused on investigating the
effects of different fabrication methods and variety of polymers on viability and
effectivity of variety of encapsulated cells47–50,

91–102

. In this work, we investigated the

effect of electrospray method of fabrication on cells encapsulated in A-PLO. Cells used
for this study were intended for therapeutic agent delivery system, ARPE-19/ CR2-fH,
and for regenerative medicine, skMDC.
Encapsulated ARPE-19 cells through our fabrication method showed that the
viability and effectivity of cells was preserved after encapsulation in Figure 3.1 and
Figure 3.2. Consequently, genetically modified ARPE-19 cells, steadily express CR2-fH
protein, proved to be viable and effective after encapsulation in Figure 3.3. ARPE-
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19/CR2-fH cells were generated in order to develop innovative therapeutic tool targeting
treatment for age-related macular degeneration (AMD). Factor H serve as an inhibitory
agent of the alternative pathway (AP) of complement activation, whereas polymorphisms
in FH are associated with AMD risk. CR2-fH, the novel recombinant form of fH, has
found to be effective inhibitor in different AP-dependent disease models such as
collagen-induced arthritis, and acute lung reperfusion injury. Importantly, CR2-fH has
shown that it is able to reduce the choroidal neovascularization (CNV) in vitro when
injected intravenously105–109. Encapsulated ARPE-19 cells expressing CR2-fH showed to
be effective in vivo as therapeutic agent delivery system. It has been presented that CR2fH was secreted in the eye from the encapsulated cells after intravitreal injection, and was
effective in reducing compliment activation and can decrease CNV in mouse93.
Primary human skeletal muscle cells (skMDC) are considered and targeted for
cell therapy110. Encapsulation of skMDC cells might be useful as a potential therapeutic
tool for treatment of severe muscle diseases and conditions. The results of this study
demonstrated that cells viability and morphology characteristics were preserved after
encapsulation in Figure 3.4. It was been showed that cells were recovered from
microcapsules in which it continue to proliferate indicating that encapsulation process did
not affect its biological characteristics. In addition, cell staining for the expression of
myogenic markers such as desmin, MyoD, and Pax-7 showed that the cells in all the
samples were able to express the targeted proteins Figure 3.5, 3.6, and 3.7 to proof that
encapsulation technique does not affect the metabolic activity of encapsulated cells.
Moreover, we showed in this work that cryopreservation of A-PLO encapsulated
cells is a feasible for future therapeutics delivery and regenerative medicine projects.
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Previous research studies have been demonstrated that cryopreservation is a promising
approach for preserving encapsulated cells for future optimization101. Encapsulated
ARPE-19 cells have been shown to preserve the viability and biological activity after
cryopreservation Figure 3.8. The goal of this approach was to generate the foundation for
cryo-banking for future utilization of encapsulated cells in regenerative medicine and
therapeutics delivery projects.
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Figure 3.1 Effect of electrospray method on encapsulation of ARPE-19 cells.
(A) ARPE-19 cells cultured in DMEM media. (B) Encapsulated cells at initial
concentration of 1x106 cells/ ml after 1 hour of encapsulation. (C) Cells after 3 days of
encapsulation. (D) Cells continue to grow inside the microencapsulation after 6 days of
incubation in media. (E) Microcapsules became full of growing cells after 20 days of
incubation in 10% FBS media. Scale bars = 100 microns.
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Figure 3.2 Viability of ARPE-19 cells after encapsulation and Recovery.
(A) Live/ dead staining performed on encapsulated cells after 3 days of encapsulation.
Viable cells stained in green (CalceinAM), whereas cells in red (Ethidium homodimer)
indicates cells with massive membrane damages. (B) ARPE-19 cells after encapsulation
and before recovery. Cells were recovered from microcapsules using sodium citrate
solution. The recovered cells have been passaged up to 3. Scale bars = 100 microns.
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Figure 3.3 Viability of ARPE-19/CR2-fH cells after encapsulation and Recovery.
(A) Live/ dead staining performed on encapsulated cells after 3 days of encapsulation.
Viable cells stained in green (CalceinAM), whereas membrane damaged (dead) cells in
red (Ethidium homodimer). (B) ARPE-19 cells after encapsulation and before recovery.
Cells were recovered from microcapsules using a sodium citrate dissolving solution. The
recovered cells have been passaged up to 3 times. Scale bars = 100 microns.
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Figure 3.4 Viability of skMDC cells after encapsulation and Recovery.
(A) skMDC cells cultured in supplemented MyoTonic media. (B) Encapsulated skMDC
cells at initial encapsulation concentration of 1x106 cells/ml. (C) Encapsulated cells after
3 days of encapsulation were stained with CalceinAM (2 M/ Green) and Ethidium
homodimer (4 M/Red). Viable cells stained in green whereas dead cells in red. (D)
skMDC were recovered from microcapsule structure using citrate sodium solution and
cultured back into supplemented MyoTonic media. (E) A Group of recovered cells was
cultured in differentiation media to allow them to differentiate and change phenotype.
Scale bars = 100 microns.
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Figure 3.5 The effect electrospray method of encapsulation on Desmin expression in
skMDC cells.
Control cells (before encapsulation), recovered, and differentiated cells were probed for
DAPI (Blue) and desmin (Red). Scale bars = 100 microns.
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Figure 3.6 The effect electrospray method of encapsulation on MyoD expression in
skMDC cells.
Control cells (before encapsulation), recovered, and differentiated cells were probed for
DAPI (Blue) and MyoD (Red). Scale bars= 100 microns.
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Figure 3.7 The effect electrospray method of encapsulation on Pax-7 expression in
skMDC cells.
Control cells (before encapsulation), recovered, and differentiated cells were probed for
DAPI (Blue) and Pax-7 (Red). Scale bars = 100 microns.
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Figure 3.8 Viability of encapsulated ARPE-19 cells after cryopreservation.
(A) Encapsulated cells thawed after freezing at -80C for 1 week. (B) Encapsulated cells
were tested for their viability after freezing. Viable cells were stained in Green
(CalceinAM), and dead cells were stained in red (Ethidium homodimer). Scale bars = 100
microns.
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CHAPTER IV3
ENCAPSULATED CELL TECHNOLOGY-BASED DELIVERY OF A COMPLIMENT
INHIBITOR REDUCES CHOROIDAL NEOVASCULARIZATION IN A MOUSE
MODEL
4.1 Background
Age-related macular degeneration (AMD) is a slowly progressing condition that is
classified according to the pathological mechanism into two categories, wet and dry
AMD.

In wet AMD, fluid accumulates in the subretinal space due to choroidal blood

vessels invasion through damaged blood barrier (BRB), and the fluid accumulation could
cause retinal detachment that consequently lead to photoreceptor deterioration as
complications of untreated condition. On the other hand, the pathological mechanisms of
dry AMD are still not clearly understood. The main characteristics of dry AMD are
degeneration of retinal pigment epithelium (RPE) and choriocapillaries that correlates to
the loss of photoreceptor cells. Involvement of genetic and environmental risk factors are
responsible on the complexity of AMD111. Wet AMD occurrence has been showed to be
associated with single nucleotide polymorphisms (SNPs) in vascular endothelial growth
factor (VEGFa), VEGFR2 receptor, and genes in the proliferation subpathway112–115;
however, there is no clear pharmacogenetic association in anti-VEGF therapy between
patient’s response to the treatment and patient’s VEGFa or VEGFR2 SNPs116,117.
3

This chapter have been excerpted from the following research article:
Annamalai B, Parsons N, Belhaj M, Brandon C, Potts J, Rohrer B. Encapsulated Cell
Technology-Based Delivery of a Complement Inhibitor Reduces Choroidal
Neovascularization in a Mouse Model. Transl Vis Sci Technol. 2018;7(2):3-3.
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In addition to the multiple SNPs in genes of the complement pathway including
polymorphisms in Y402H variant in the complement inhibitor factor H (CFH) which are
linked with an increased risk of developing AMD118. According to association between
AMD and Y402H, this study focused on investigating complement activation
mechanisms in AMD models as well as examining improvements in complement
therapeutics for treatment of AMD pathologies.
The complement system is a part of innate immune system that is activated in
response to stress and/or injury stimulators. The activation of the complement systems
followed by multiple biological molecules activation cascade including C3a and C5a
(anaphylatoxins), opsonins C3d and C3dg (opsonization of damaged cells), membrane
attach complex (MAC- lysis of cells)119. A complement inhibitor molecule (CR2-fH) has
been developed and effectively inhibits complement activation at RPE levels in vitro in
AMD models120–122. In addition, CR2-fH has been shown via in vitro models that it was
effective in reducing choroidal neovascularization (CNV) development by suppressing
complement activation and VEGF production123–125. Moreover, CR2-fH has shown
effectivity as an inhibitor indifferent AP dependent disease conditions such as collagen
induced arthritis, and acute lung and ischemia perfusion injury126,127. The inhibitory
activity of CR2-fH is prompted due to presence of AP-inhibitory domain that linked to a
complement receptor (CR2) and targets the inhibitor fH to bind complement activation
products128. Importantly, the efficacy and safety of subretinal administration of AAV
vector encoding the CR2-fH inhibitor has been confirmed in mouse model of CNV129. In
the current study, efficacy of delivering CR2-FH using encapsulation technique to
encapsulate genetically modified ARPE-19 cells has been examined in mouse CNV
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model. The small size of produced alginate microcapsules is required for intravitreal
injections into the eye of an experimental mouse.
4.2 Materials and Methods
Cells Culture:
ARPE-19 cells, a human RPE cell line that express the differentiated phenotype
of RPE cells. The plasmid constructs of CR2 and CR2-fH were transfected into ARPE19 cells with FuGene HD transfection reagent according to the manufacturer’s
instructions (Roche Applied Science, Indianapolis,IN). Stable expression in a mixed
population was produced by L-methionine sulfoximine antibiotic selection. Secreted
protein into apical and basal compartments was monitored in polarized RPE grown on
transwell plates121. The molecular weight of CR2-fH was examined using sodium
dodecyl sulfate acrylamide gel electrophoresis (SDS-PAGE; data not shown). The cells
were cultured in High glucose/without L-glutamine- Dulbecco's Modified Eagle Medium
(Sigma Aldrich) supplemented with10%

dialyzed FBS (Sigma Aldrich), 2%

Glutamine synthetase expression medium (GSEM- Sigma Aldrich), and 0.28l/ml Lmethionine sulfoximine (MSX- Sigma Aldrich). The medium was replaced every 2-3
days, and the cells were passaged after 70%-80% confluence was reached. Cells were
used between third and fifth passage.
Cells Encapsulation:
Electrospray method of microencapsulation has been used to encapsulate the
targeted cells. In this method, sodium alginate (Sigma-Aldrich) was mixed with DI water
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under sterile conditions at concentration of 2% w/v and purified by filtration at 0.2 mm.
Alginate solution (300 l aliquots) were loaded into a 3cc syringe and attached to a
syringe pump, and pumped through a needle (30G blunt tip; Small Parts, Inc.,
Logansport, IN, USA) to a gelling bath placed in a beaker below the syringe at 7 mm of a
needle to bath spraying distance. The gelling bath contains a volume of 40 mL of 10 mM
HEPES buffered saline containing 100 mM calcium chloride (CaCl2) (Sigma-Aldrich),
and 0.5% w/v poly-L-ornithine (PLO) (Alfa Aesar) that forms a second coating to the
microcapsules as one step method for adjusting the porosity. The needle tip connected to
a high voltage generator while the gelling bath grounded. By applying high voltage
between positive and grounded bath, alginate is extruded from the needle tip to the
gelling bath where calcium ions (Ca2+) replace sodium ions (Na+) forming alginate
microcapsules coated with PLO and cells mixed with alginate solution will be trapped
inside the microcapsules. Cells were trypsinized, centrifuged, and washed with 10 mM
HEPES buffered saline solution (pH 7.4), and a final cell concentration of 1x106 in
alginate solution were adjusted. Constant parameters of 60mm/h flow rate and 8.0 kV
voltage were adjusted to produce microcapsules size of 150 m. Formed microcapsules
containing cells were washed with washing solution (10 mM HEPES buffered saline
containing 1.5 mM CaCl2, pH 7.4) twice, and then incubated with suitable media in a
humidified incubator at 37C and 5% CO2.
Cells Recovery:
The cells were released from alginate microcapsules by adding 55 mM Sodium
citrate in 10 mM HEPES buffered saline (pH 7.4) to the encapsulated cells with gentle
shaking for 5 mins at room temperature. In this step, calcium ions will replace sodium
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ions in the microcapsule structure resulting in diluted sodium alginate and releasing the
cells from the microcapsules. Furthermore, the cells were centrifuged at 1200 rpm for 5
mins and incubated with media at 37C and 5% CO2 for 24 hrs.
Cells Viability (Live/Dead) Assay:
After incubating the encapsulated cells for 24 hours, approximately 30
microcapsules were washed twice with washing solution (10 mM HEPES buffered saline
containing 1.5 mM CaCl2) and stained for live-dead viability. Live/Dead assay kit
(Molecular Probes) was used to evaluate the viability of cells after encapsulation.
According to the manufacturer’s instructions, CalceinAM indicated viable cells by green
fluorescence (excitation/emission 495/515 nm), whereas Ethidium homodimer-1
indicated dead cells by red fluorescence (excitation/emission 495/635 nm).
Encapsulated cells in washing solution were mixed with Calcein AM and Ethidium
homodimer-1 at final concentrations of 2 M and 4 M respectively, and incubated for
30-45 mins in dark at room temperature. After staining, microcapsules were washed
twice with washing solution and imaged using Invitrogen EVOS FL Auto Cell Imaging
System (Thermo Fisher Scientific, Waltham, MA).
Microcapsule injections:
C57BL/6J mice 8-10 weeks of age of both sexes were used in this study (Jackson
Laboratory, Bar Harbor, ME) that were bred in the facility animal house. All the
experiments were carried out in compliance with the Guide for the ARVO Statement for
the Use of Animals in Ophthalmic and Vision Research and were approved by the
Animal Care and Use Committee at the Medical University of South Carolina. Prior to
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intravitreal injections, mice were placed under using an anesthesia mixture of (xylazine
and ketamine, 20 and 80 mg/kg, respectively) applied by intraperitoneal injection.
Phenylephrine HCL (2.5%) and atropine sulfate (1%) were used to dilate the mouse’s
pupils. Under dissecting microscope, an amount of 1 L of DMEM containing
microcapsules with CR2-fH- or CR2-expressing ARPE-19 cells, native ARPE-19 cells,
or no content was injected intravitreally with a 27G needle attached to a Hamilton syringe
angled at 45-degree during the injection to avoid the lens. Before injecting the
microcapsules, the sclera was punctured at the limbus with a 25G needle. Post injection,
antibiotic ointment was applied to the animals’ eyes.
Laser CNV:
Argon laser photocoagulation (532 nm, 100-lm spot size, 0.1- second duration,
100 mW) was used one month post injection to create four laser spots around the optic
nerve of each eye124. Bruch's membrane (BrM) rupture was confirmed by bubble
formation at the laser burn site where those lesions only were used for lesion growth
assessment130. Five days post CNV induction, mouse eyes were imaged using optical
coherence tomography (OCT) before scarifying the animals on day 6 for tissue
collection.
Dot blot and Western Analysis:
Examining CR2-fH production from transfected cells—Cell lysates were
collected after centrifugation (20,000g for 30 minutes at 48C). 25 l of total protein was
loaded into 96- well plate and samples were transferred on a nitrocellulose membrane
using the Bio-Dott Microfiltration Apparatus (Bio-Rad Laboratories, Inc. Hercules, CA).
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The dotted membrane blocked in 5% nonfat milk in TBST buffer for 2 hours at room
temperature after being washed with Tris-buffered saline and 0.1% Tween 20 (TBST)
wash buffer. After blocking, the membranes were incubated overnight with primary
antibody against CR2 at 1:1000 dilutions in 5% nonfat milk/ TBST. Horseradish
peroxidase- conjugated secondary antibody (anti-rat; Santa Cruz Biotechnology, Inc.,
Dallas, TX) was used for visualization followed by incubation with Claritye Western
ECL Blotting Substrate (Bio-Rad Laboratories, Inc.).
Examining antibody generation in mice against secreted CR2-fH following
intravitreal administration of ARPE-19 cells—Supernatants from CR2-fH-expressing
cells were added to Laemmli sample buffer and boiled. Two different concentrations of
the samples were separated electrophoretically using 4%–20% Criterione TGXe Gels
(Bio-Rad Laboratories, Inc.). Proteins were then electro-transferred to PVDF membranes,
and incubated with primary antibody against CR2, or serum (1:50) from mice treated
with intravitreal CR2- or CR2-fH microcapsules. Horseradish peroxidase-conjugated
secondary antibody (antimouse IgG and IgM; Santa Cruz Biotechnology) was used for
visualization followed by incubation with Claritye Western ECL Blotting Substrate and
chemiluminescent detection (Bio-Rad Laboratories, Inc.).
Immunohistochemistry:
Tissue samples of eye lens and anterior chamber were removed from eyecups
which was collected as showed in previous study124, and the samples were then fixed
overnight with 4% paraformaldehyde (PFA). After thoroughly washing in PBS, samples
were embedded in Neg-50 cutting medium (Richard-Allen Scientific; Thermo Fisher
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Scientific) and sectioned into 14-m sections using a cryostat. Blocking solution
consisting of (10% normal goat serum, 3% bovine serum albumin factor V, and 0.4%
Triton-X in PBS) was used to block the sections before staining overnight with (1:200)
CR2 (7G6) antibody at 4C. after washing the stained sections with blocking solution,
secondary antibody was added (Alexa Fluor 488 goat anti-mouse IgG; 1:500; Invitrogen)
and mounted using Fluoromount (Southern Biotechnology Associates, Inc., Birmingham,
AL). Images were obtained by fluorescence microscope (Zeiss, Thornwood, NY).
Optical Coherence and Tomography:
SD-OCT Bioptigent Spectral Domain Ophthalmic Imaging System (Bioptigen,
Inc., Durham, NC) was used to visualize the injected microcapsules in the eye and to
analyze CNV lesion size after 5 days of laser treatment as has been described in previous
studies131,132. For the analysis of CNV lesion, rectangular volume scan images set at 1.63
1.6 mm were acquired which consists of 100 B-scans (1000 A-scans per B scan)as well
as measurements of cross-sectional area of the lesion using the en-face fundus
reconstruction tool. The center of the lesion was determined passing through the RPEBrM rupture with the axial interval positioned at the level of the RPE/choroid complex as
described in previous work133. Image J software for date analysis (Wayne Rasband,
National Institutes of Health, Bethesda, MD; available online) was used to measure the
area around the hyporeflective spot produced on the fundus image, with vertical calipers
set at 0.100 mm at the site of each lesion.
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C3a ELISA:
Mouse complement C3a ELISA (LifeSpan Biosciences, Inc., Seattle, WA) was
used to perform C3a ELISA according to the manufacturer’s protocol. The RPE/ choroid
tissues were ultrasonicated with 500 L ice cold PBS (lysing process) after being
thoroughly rinsed with ice cold PBS to remove excess blood. The homogenized sample
was centrifuged at 5000g for 5 minutes, and then the assay performed according to the
manufacturer’s instructions. Standards of C3a were used along with samples, and the
absorbance was read at 450 nm using microplate reader.
Statistics:
Unpaired t-tests was used for single comparison, and ANOVA (Fisher PLSD) was
used for in-between group analysis with P value = 0.05 for significance (StatView, Cary,
NY). Data are reported as mean ± SEM.
4.3 Results
Encapsulation of genetically modified ARPE-19 cells—secretion of CR2 and
CR2-fH was confirmed by dot analysis using collected supernatants from cells grown as
stable monolayers on transwell plates as shown in Figure 4.1 (D). Encapsulation of
genetically modified ARPE-19 cells within 2% alginate microcapsules was successfully
accomplished and it has been confirmed by brightfield microscopy Figure 4.1 (A).
Viability of encapsulated cells post encapsulation was assessed using live dead assay that
showed a viability of 90% of encapsulated cells Figure 4.1 (C). After dissolving the
microcapsule structure using sodium citrate solution, ARPE-19 cells viability has been
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assessed by incubating the cells back into their desired media where they have been
grown for 90% confluency Figure 4.1 (B).
Delivery of encapsulated ARPE-19 cells intravitreally—the microcapsules size
was adjusted through the encapsulation method to produce microcapsules at an
approximate size of 150 l as an optimum size. The optimum size was ideal to be
injected through 27G needle which its inner diameter 210m, and to minimize the
microcapsules during intravitreal injection. OCT imaging was performed after injecting
the microcapsules in the vitreous of mouse’s eye to examine the presence of intact
microcapsules in that area as indicated in Figure 4.2 (A). In addition, presence of CR2FH in the microcapsules as well as its secretion into the vitreous and retinal tissue has
been confirmed using immunohistochemistry Figure 4.2 (B). Moreover, it has been
confirmed that CR2-fH specifically retained in CNV injury site compared to sites without
CNV lesions by dot blot analysis of RPE/choroid fractions as shown in Figure 4.2 (C)
and as previously reported in previous study134. Examining antibody production against
secreted CR2-fH which might access the blood stream has been performed. Mouse serum
was collected after 1 month of microcapsules injection and tested for anti-CR2-fH
antibody production. It has been shown that neither IgG nor IgM antibodies recognizing
CR2-fH could be identified in both CR2-fH microcapsules injected group or control
group Figure 4.3. Similar results were previously reported when mice were systemically
injected with CR2-fH protein135.
Effects of secreted CR2-fH on reducing complement activation and attenuating
CNV development—the effect of secreted CR2-fH on CNV lesion size has been
evaluated after 5 days of laser-induced photocoagulation. Experimental mice were
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injected intravitreally with alginate microcapsules loaded with ARPE-19 expressing CR2,
ARPE-19 expressing CR2-fH, native ARPE-19, or empty microcapsules. It has been
reported in this study that lesion size in animals received microcapsules with cells
expressing CR2-fh reduced significantly (P0.02) compared to other experimental animal
groups as demonstrated in Figure 4.4 (A,B). Moreover, ELISA measurements showed
significant reduction in C3a levels in mice injected with microcapsules containing cells
expressing CR2-fH Figure 4.4 (C). This reduction was expected because it has been
known previously that the presence of factor H prevents C3-convertase formation. On the
other hand, animals injected with microcapsules loaded with cells expressing CR2, native
cells, or empty microcapsules showed an increase in C3a in RPE/choroid fractions.
4.4 Discussion
The focus of this study was to investigate the effectivity of encapsulation
technique in encapsulating cells as cell therapy approach to deliver CR2-fH to the eye as
a therapeutic strategy for complement dependent diseases. It has been demonstrated
through this study that encapsulation technique can preserve the viability of encapsulated
ARPE-19 cell within alginate based microcapsules. The encapsulated cells showed
secretion activity of CR2-fH that is able to diffuse into the vitreous of the mouse while
anti-CR2-fH antibody was not detected. Importantly, secretion of CR2-fH by
encapsulated ARPE-19 cells in the eye showed a great effect on reducing CNV
development as well as complement activation. Indeed, the obtained results propose the
effectivity of encapsulated cell therapy as a therapeutic strategy in treating wet AMD.
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It has been recently discussed that the essential aim of encapsulated cells as a
therapy approach is to provide a sustain release delivery of therapeutics secreted by
encapsulated cells without triggering the immune response against it136. According to the
present study, the viability of encapsulated cells was preserved and the cells were able to
be recovered from the alginate microcapsules to continue proliferating after plating and
incubating them back in media. Also, it was confirmed by dot blot analysis that cells
secreted CR2-fH for 1 to 2 months after cells being encapsulated and injected; however,
antibodies against CR2-fH were not generated by testing CR2-fH antibodies (IgG and
IgM). On the other hand, antibodies formation against ARPE-19 epitopes have never
been tested in this work because according to a number of clinical trials it has been
shown that immunosuppressants are not required while utilizing devices loaded with
ARPE-19 cells137,138.
In biotechnology industry world, Neurotech is a biotechnology company focused
on the development of encapsulated cell therapy as a therapeutic approach for chronic
eye diseases. Neurotech has loaded ARPE-19 cells into a device (NT-501) that has been
tested in the eye in which it is delivering CNTF and NT-503, a soluble anti-VEGF-R
protein. NT-501 had a good safety results and ongoing trials in glaucoma and Macular
Telangiectasia type 2 are taking place to deliver CNTF. However, delivering NT-503
protein using this device has been discontinued in phase II trial because rescue
medications were highly required in the treatment arm by a large number of patients
according to Neurotech Company. Also, according to Neurotech, it is very important to
consider the fact that ARPE-19 cells secrete not only therapeutic proteins but also other
proteins consistently that might interfere with the efficacy of the targeted therapeutic
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proteins. It has been demonstrated that ARPE-19 cells secret a diversity of proteins that
are involved in maintenance and regulation of the complement pathway, extracellular
matrix, inflammatory responses, and angiogenesis139. The quantity and the composition
of proteins secreted can vary according to the eye under specific disease or treatment
application technique; however, the effect of delivering encapsulated ARPE-19 cells on
protein secretion and composition has not been determined in this study. Indeed in this
work, data show the presence of ARPE-19 in the mouse eye do not interfere with the
growth of CNV lesion, but also active CR2-fH showed a protective effect comparing to
the inactive CR2, the native cells, or the empty microcapsules Figure 4.4 (B). Moreover,
complement activation has not been affected by the presence of ARPE-19 cells in the
mouse eye according to the measurements of complement C3a, and this has been
determined through the effect of encapsulated native ARPE-19, encapsulated ARPE-19
expressing CR2, and empty microcapsules Figure 4.4 (C). The concentration of
microcapsules loaded with ARPE-19 expressing CR2-fH loaded reduced complement
activation effectively to the base line levels. The preliminary data of this study showed
that approximately 30 microcapsules were responsible on reducing the complement
activation and interfere with CNV development. Accordingly, delivering the therapeutic
dose of CR2-fH via cell encapsulation technique will promote normal functions of the
complement system that is envision as a mediator as a global mediator in immune
surveillance, cell homeostasis, and tissue development and repair140.
ARPE-19 cells have a potential of initiating complications on disease outcomes
when they being used a therapeutic approach. The need of delivering anti-complement
materials is a necessity, and AAV gene therapy is considered an attractive tool that has
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been utilized for disease models141. The expression of the inhibitor in dry or wet AMD
should be inducible when required when new CNV lesion being developed, and it can be
repressed once the inhibitory effect is no longer needed to avoid the toxic effects of
excessive treatment. It has been demonstrated previously that using expression system
that can be controlled exogenously, rapamycin or RU486 regulation, or endogenously,
hypoxia response element (HRE), could be a feasible approach in controlling CR2-FH
overtreatment, especially in case of HRE since hypoxia is highly correlated to wet
AMD142.
This study showed that encapsulated cells therapy has been used to deliver the
AP-complement inhibitor factor H using genetically modified ARPE-19 cells to the eye
at complement activation sites. The inhibition of AP complement activation reduces
complement activation, slows CNV development, and allows retention of physiological
levels of complement required for cellular homeostasis and immune surveillance140.
Future investigations are recommended to examine the feasibility of cell
encapsulation-mediated therapeutic delivery of a complement inhibitor as a potential long
term inhibition approach in the smoke-induced ocular model125, as well as in dry AMD.
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Figure 4.1 Encapsulation technique development to encapsulate genetically modified
ARPE-19 cells to deliver CR2-fH.
(A) Encapsulated ARPE-19 cells in culture. (B) Recovered cells after dissolving the
microcapsule alginate structure and incubated in culture to examine viability. (C) Cell
viability within the microcapsules was assessed using live/ dead assay where Calcein AM
indicating live cells (Green) and Ethidium homodimer-1 indicating dead cells (Red).
Secreted CR2 and CR2-fH towards both the apical and basal side from the stably
transfected ARPE-19 cells that were grown as monolayers on transwell plates ( secretion
assessed from three different cultures).
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Figure 4.2 Assessment of delivering CR2-fH using encapsulation technique in the eye.
(A) The microcapsules were detected in the eye using optical coherence tomography
(OCT). (B) Immunohistochemistry was used to confirm production and diffusion of CR2fH protein from the microcapsules throughout the retina layers via antibody staining
against CR2. Results were compared between uninjected control eyes and injected eyes
where the staining was negative in the control. (C) A dot blot of RPE/choroid samples
were used to detect CR2-FH after intravitreal injection of the microcapsules in the
RPE/choroid region of the eye with CNV lesions or without. CR2-fH was detectable in
the samples with CNV lesions comparing to the other group. Results are shown from
more than three independent experiments.
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Figure 4.3 Immune response measurements against CR2-fH produced in the eye.
After one month of injecting encapsulated ARPE-19 cells expressing CR2 and CR2-fH,
production of IgG or IgM were not detected. Two different concentrations of expressed
CR2-fH were probed against anti-CR2 for the presence of CR2-fH in the supernatants in
order to identify the size of the protein (positive control).Serum from both groups,
experimental (S-E; injected with CR2-fH capsules) and control (S-E; age-matched
animals without injections S-C), was used for probing at 1:50 followed by appropriate
secondary antibodies.
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Figure 4.4 Delivered CR2-fH through encapsulation technique reduces CVV and
complement activation.
Laser induced CNV was performed after one month of injecting encapsulated cells
intravitreally. 5 days later, lesion spot sizes were analyzed using OCT and complement
activation was assessed for anaphylatoxin C3a using ELISA. (A, B) CNV lesion sizes
were reduced in the eyes of experimental group injected with encapsulated ARPE-19
expressing CR2-fH compared to other groups, encapsulated cells expressing CR2, native
ARPE-19 without cargo, or empty alginate microcapsules. (C) C3a levels in RPE/choroid
fractions were elevated in animals injected with encapsulated ARPE-19 expressing CR2,
encapsulated native ARPE-19, and empty microcapsules. Levels of C3a were reduced
significantly in animal groups injected with encapsulated CR2-fH expressing cells.
Control group represents animals with no CNV lesions. Data shown are average values
(6SEM) (n ¼ 3–18 animals per condition as indicated).
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CHAPTER V
INVOLVEMENT OF HYDROGEL SYSTEMS IN ADVANCING
ALGINATE BASED MICROCAPSULES
5.1 Background
Hydrogels have been utilized as scaffold polymers in different approaches
including therapeutic agent delivery and regenerative medicine. There are a variety of
applications in which hydrogels have been targeted such as delivery agents for bioactive
materials, as three-dimensional structures that can organize cells and direct the formation
of a desired tissue with presence of specific stimuli, as well as their application as space
filling agents68. Properties including mechanical properties, swelling, diffusion, and
degradation are important to the hydrogel crosslinked structure in which they are control
the hydrogel utilization for each specific approach143. Type I collagen has been used
widely as a viable scaffold for various applications; however, collagen scaffold properties
can vary according to the fabrication protocol used by different researchers. Collagen
source and gelation pH are significant fabrication parameters that contribute to identify
hydrogel properties and applications68,76,144–148.
The main goal of this study is developing new approach through embedding APLO microcapsules in collagen hydrogel as an enhanced delivery system. Through this
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study we will show the successful implementation of lyophilized microcapsules as well
as our encapsulated cells within collagen hydrogel.
5.2 Materials and Methods
Collagen hydrogels:
To prepare the hydrogels for incorporation of the lyophilized microcapsules, we
used type I bovine collagen (Purecol, Advanced Biomatrix, San Diego, CA), 0.2N
HEPES buffer pH9.0, and 10X Minimal Essential Medium (MEM) at proportions of
8:1:1 accordingly. Lyophilized microcapsules were added immediately after mixing the
hydrogel contents then aliquots of 300 l of the mix poured into 24 well plates. The plate
was then incubated at 37C for 30 minutes to let it polymerize, then we added deionized
water to keep hydrated.
To prepare the hydrogels for incorporation of the encapsulated ARPE-19 cells, we
used type I bovine collagen (Purecol, Advanced Biomatrix, San Diego, CA), 0.2N
HEPES buffer pH9.0, and 10X Minimal Essential Medium (MEM) at proportions of
8:1:1 accordingly. Encapsulated ARPE-19 cells were mixed with freshly prepared
hydrogel gel after aspirating the media from the microcapsules. Appropriate aliquots 300500l of the mix were poured into 24 well plate; then incubated at 37C/ CO2 for 30
minutes to let the hydrogel to polymerizing. Media was added after the hydrogel
containing cells had been polymerized.
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5.3 Results
Lyophilized microcapsules in hydrogel:
Lyophilized microcapsules were mixed with freshly prepared type I collagen
hydrogel and incubated for 30 minutes at 37C in order for the hydrogel to polymerize.
Rehydration of lyophilized microcapsules were investigated under light microscope to
verify that microcapsules were able to rehydrate within the hydrogel and retain their
original shape (spherical) Figure 4.1 (B).
Encapsulated cells in hydrogel:
Encapsulated cells were mixed with freshly prepared type I collagen hydrogel and
incubated at 37C for 30 minutes. After polymerization of the hydrogel, we added media
on the top of the hydrogel and we incubate it at 37C and 5% CO2 as it is shown in
Figure 4.2 (B). Live/ dead assay was performed to test encapsulated cells viability within
the hydrogel, and it was demonstrated that cells were still preserving their viability in
Figure 4.2 (C) where live cells expressed in green.
5.4 Discussion
Hydrogels are natural and synthetic three-dimensional systems with hydrophilic
polymer chains which provide ability to hold high content of water. They have broad uses
in biomedical research including drug delivery, regenerative medicine, and tissue
engineering.58,61,149–151. The diversity of hydrogel applications is dependent upon the
special traits of hydrogel that spans from biocompatibility, adjustable chemical
properties, ability to mimic extracellular matrix, and serve as growth medium151 . As an
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attempt to further improve A-PLO microcapsules for therapeutic applications, we utilized
the lyophilized microcapsules and encapsulated cells to be mixed with type I collagen
hydrogel. Our study shows that lyophilized microcapsules have the ability to rehydrate
after being mixed with the hydrogel during its polymerization. The lyophilized
microcapsules were empty; however we are demonstrating the effectiveness of the
system as a tool for application in which the microcapsules can be filled with different
therapeutic materials. Moreover, we also demonstrated the ability of the encapsulated
ARPE-19 cells to be loaded into type I collagen hydrogels in which it can be used for
regenerative medicine and as a delivery system.
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Figure 5.1 Lyophilized microcapsules and their rehydration after mix with collagen
hydrogel.
(A) Microcapsules appear shrunk and dried after lyophilization. Lyophilized
microcapsules rehydrated and returned their spherical shape again after mix with type I
collagen hydrogel. Scale bars = 50 microns.

Figure 5.2 Viability of encapsulated ARPE-19 cells embedded within type I collagen
hydrogel.
(A) Encapsulated ARPE-19 cells in DMEM media. (B) Encapsulated cells embedded in
the hydrogel gel and incubated with media. (C) Encapsulated cells within the hydrogel
were stained for their viability via live/dead assay. The Green was an indication of cell
viability while the red indicated the damaged cells. Scale bars= 100 microns.
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CHAPTER VI
SUMMARY AND FUTURE WORK

Summary
Electrospray microencapsulation has been used in our lab previously to show
enhanced wound healing in a rodent model. The previous work concentrated on the
encapsulation of a small peptide known as CT185; in addition, we have had success in
encapsulating different constituents such as proteins, antimicrobial agents, and even cells.
In this work, I was able to show several enhancements to the original encapsulation
technique for both wound healing and cell therapy. I was able to lyophilize the alginatePLO microcapsules without damaging their morphology following rehydration with the
addition of DI water or Tyrodes buffer. Interestingly the microcapsules regain their
spherical shape with some surface irregularity. I was also able to show that addition of
lyophilized microcapsules to a gelling collagen matrix also showed the ability to hydrate
back into their original spherical shape. To investigate the process for cell based
therapies, I was able to encapsulate various cell types using the same method of
encapsulation by tweaking the voltages and flow rates for optimum cell viability, and
showed the ability of the cells to survive the voltage applied during microencapsulation
technique. Encapsulated cells (ARPE-19, genetically engineered ARPE-19, and skMDC)
were tested for viability after encapsulation using live/ dead assay, and the cells types
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were shown to be viable within the microcapsules. We took this to an in vivo model of
age related macular degeneration (AMD) and showed that addition of genetically
modified ARPE-19 cells expressing the protein CR2-fh was able to ameliorate the
symptoms of AMD in a mouse model. To determine whether the encapsulation process
had interfered with the cells proliferative ability, we tested the cells when dissolved from
the capsules and demonstrated their ability to continue to proliferate in culture and were
passaged multiple times thereafter. Finally, we showed that the skMDCs retained several
key markers, Pax7, desmin and MyoD following dissolving and further culturing.
Indicating that the encapsulation process is not affecting the cells proliferative
capabilities nor losing their inherent genetic profile.
We also demonstrated our ability to cryopreserve the microencapsulated cells for
a period that resembles long term storage for future experimental use, and showed their
viability after thawing and culturing in media. We froze the encapsulated cells and stored
them at both -80C and also liquid nitrogen. Cells frozen in both conditions showed the
ability to regain their growth potential. Finally, encapsulated cells were incorporated
successfully within type I collagen hydrogels where the cells preserved their viability
while cultured within this system which can be further utilized for tissue engineering and
sustain release delivery of therapeutics.
Future Work
Presented here is a promising technique that can be tuned for its utilization
according to each approach discussed in this study. Further investigations are needed for
the effect of lyophilization on release profiles of materials such as CT1, and BSA
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loaded A-PLO microcapsules; a complete and comprehensive analysis of loaded
lyophilized microcapsules for their sustained release and therapeutic effect on wound
healing needs further investigation. In the future encapsulation of multiple cell types in
the capsules is planned. It’s believed that the cells interact in vivo could in fact be
encapsulated to mimic their in vivo interactions. We would also begin examining the
ability to further coat the microcapsules with antibodies to further target the addition of
the microcapsules within the body to certain tissues or cells. Additionally, a single report
exists of the ability to lyophilize microencapsulated cells. We plan to further our initial
work to determine if this is another viable option of our system. Finally, we plan to
generate an animal model for skeletal muscle atrophy and/or degeneration and use our
encapsulated skMDCs to fully evaluate the therapeutic potentials of encapsulating
skMDC cells in these types of muscle diseases. Thus providing us a true bench top to
bedside application in the future.
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